



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant: Cristina M. Rondinone, *et al.*

Serial No.: 10/074,194

Filed: February 12, 2002

For: METHODS FOR IDENTIFYING  
COMPOUNDS THAT INHIBIT OR  
REDUCE PTP1B EXPRESSION

Examiner: (not assigned)

Group Art Unit: 1743

Case No.: 6792.US.01

CERTIFICATE OF MAILING (37 CFR  
1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents  
Box Non-Fee  
Washington, D.C. 20231, on:

Date of Deposit: October 4, 2002

Wanda C. Smith  
Wanda E. Smith

10/4/02  
Date

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Box Non-Fee  
Washington, D.C. 20231

Dear Sir:

RECEIVED  
OCT 09 2002  
TC 1700

This information disclosure statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR § 1.97(b).

The Applicants submit herewith Form PTO 1449 listing the references cited for this Information Disclosure Statement.

The Applicants respectfully request that the Examiner initial next to each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and that a copy of the initialed Form PTO 1449 be returned to Applicants.

No charge is required for the submission of this Information Disclosure Statement under 37 C.F.R. § 1.97 (b). The Commissioner is hereby authorized to charge any additional filing fees required under 37 C.F.R. § 1.17 concerning this transmission, or to credit any overpayment to Deposit Account No. 01-0025.




23492

ABBOTT LABORATORIES  
Telephone: (847) 937-4559  
Facsimile: (847) 938-2623

Respectfully submitted,  
Cristina M. Rondinone, *et al.*

Daniel W. Collins  
Daniel W. Collins  
Registration No. 31,912  
Attorney for Applicants

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6792.US.01

SERIAL NO.

10/074,194

APPLICANT

B. Zinker, et al.

FILING DATE

February 12, 2002

GROUP

1743

 RECEIVED  
 OCT 09 2002  
 TC 1700

## U.S. PATENT DOCUMENTS

EXAMINE R INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
B1	0 1 1 9 8 3 0	22.03.2001	WO			
B2	0 1 1 9 8 3 1	22.03.2001	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Ahmad, et al., "Increased Abundance of Specific Skeletal Muscle Protein-Tyrosine Phosphatases in a Genetic Model of Insulin-Resistant Obesity and Diabetes Mellitus", <i>Metabolism</i> , 44(9):1175-1184 (1995)
C2	Calera, et al., "Dynamics of Protein-tyrosine Phosphatases in Rat Adipocytes", <i>Journ. Biol. Chem.</i> , 275(9):6308-6312 (2000)
C3	Elchebly, et al., "Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B Gene", <i>Science</i> , 283(5407):1544-1548 (1999)
C4	Goldstein, et al., "Tyrosine Dephosphorylation and Deactivation of Insulin Receptor Substrate-1 by Protein-tyrosine Phosphatase 1B", <i>Journ. Biol. Chem.</i> , 275(6):4283-4289 (2000)
C5	Inukai, et al., "p85 $\alpha$ Gene Generates Three Isoforms of Regulatory Subunit for Phosphatidylinositol 3-Kinase (PI 3-Kinase), p50 $\alpha$ , p55 $\alpha$ , and p85 $\alpha$ , with Different PI 3-Kinase Activity Elevating Responses to Insulin", <i>Journ. Biol. Chem.</i> , 272(12):7873-7882 (1997)
C6	Kenner, et al., "Protein-tyrosine Phosphatase 1B Is a Negative Regulator of Insulin- and Insulin-like Growth Factor-I-stimulated Signaling", <i>Journ. Biol. Chem.</i> , 271(33):19810-19816 (1996)
C7	Mater, et al., "Sterol Response Element-Binding Protein 1c (SREBP1c) Is Involved in the Polyunsaturated Fatty Acid Suppression of Hepatic S14 Gene Transcription", <i>Journ. Biol. Chem.</i> , 274(46):32725-32732 (1999)
C8	McGuire, et al., "Abnormal Regulation of Protein Tyrosine Phosphatase Activities in Skeletal Muscle of Insulin-Resistant Humans", <i>Diabetes</i> , 40:939-942 (1991)
C9	Salmeen, et al., "Molecular Basis for the Dephosphorylation of the Activation Segment of the Insulin Receptor by Protein Tyrosine Phosphatase 1B", <i>Molecular Cell</i> , 6:1401-1412 (2000)
C10	Seely, et al., "Protein Tyrosine Phosphatase 1B Interacts With the Activated Insulin Receptor", <i>Diabetes</i> , 45:1379-1385 (1996)
C11	Shimomura, et al., "Nuclear Sterol Regulatory Element-binding Proteins Activate Genes Responsible for the Entire Program of Unsaturated Fatty Acid Biosynthesis in Transgenic Mouse Liver", <i>Journ. Biol. Chem.</i> , 273(52):35299-35306 (1998)
C12	Terauchi, et al., "Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 $\alpha$ subunit of phosphoinositide 3-kinase", <i>Nature Genetics</i> , 21:230 (1999)

EXAMINER

Alexander

DATE CONSIDERED

8/27/03

EXAMINER: Initial citation consider d. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)